Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data
Authors:
- David F. McDermottDMDavid F. McDermott
- Daniel J. GeorgeDGDaniel J. George
- 1 May 2010
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 36 (3) , 216-223
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sequential Sorafenib and Sunitinib for Renal Cell CarcinomaJournal of Urology, 2009
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Journal of Clinical Oncology, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Steroid Hormone Receptor Expression in Renal Cell Carcinoma: An Immunohistochemical Analysis of 182 TumorsJournal of Urology, 2004
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993
- Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinomaNature, 1988